How do we optimize treatment sequencing in MPC to maximize the clinical benefit for our patients?

Program and Faculty of the satellite symposium organized by Celgene

Thomas Seufferlein, MD (Chair) Universitätsklinikum Ulm, Ulm, Germany
Philip Agop Philip, MD PhD FRCP, Wayne State University & Karmanos Cancer Institute, Detroit, MI, USA
Michele Reni, MD IRCCS San Raffaele Scientific Institute, Milan, Italy
 
  • Welcome and introduction (Thomas Seufferlein)
  • How do we optimize treatment sequencing in MPC? Opportunities and limitations of clinical evidence (Philip Agop Philip)
  • Italian experience of treatment sequencing in MPC (Michele Reni)
  • Practical application of current evidence to optimize treatment sequencing in MPC (all, led by Thomas Seufferlein, Germany)
  • Summary and close (Thomas Seufferlein)
 

Welcome and introduction

  • Thomas Seufferlein, Germany:

   

How do we optimize treatment sequencing in MPC? Opportunities and limitations of clinical evidence

  • Philip Agop Philip, USA:

     

Italian experience of treatment sequencing in MPC

  • Michele Reni, Italy:

     

Practical application of current evidence to optimize treatment sequencing in MPC

  • All, led by Thomas Seufferlein, Germany:

     

Summary and close:

  • Thomas Seufferlein, Germany: